Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Core Insights - Lifeward is positioned as a diversified biomedical innovation company with a clear path to profitability through its strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology [1][2][3] Financial Aspects - The partnership allows Lifeward access to up to $47 million in capital through various funding mechanisms, including equity and milestone-based funding [3][4] - Lifeward aims to drive profitability from its established medical technology product portfolio while investing in complementary technologies [4][8] Strategic Opportunities - The integration of the POD™ platform provides Lifeward exposure to a significant biotechnology market, particularly in oral delivery of biologic drugs, which could transform treatment for chronic diseases [5][6] - The POD™ technology has been evaluated in clinical programs for diabetes, a market exceeding $80 billion annually, indicating substantial growth potential [6][7] Operational Focus - Oramed will manage and fund the clinical development of the POD™ platform, allowing Lifeward to concentrate on its existing MedTech business while benefiting from the biotechnology platform's potential [7][8] - Lifeward's strategy includes building a diversified biomedical portfolio that balances immediate revenue generation with long-term innovation opportunities [13]